https://mtimes.net/article/1413 MTIMES Global en 2026-11-01T23:10:21.054Z Suprema: Moving Beyond Facial Recognition to Intelligent Spaces, Says Small Insight Research https://mtimes.net/article/1410 MTIMES Global en 2026-11-01T03:17:17.179Z KOSDAQ under siege: Calls mount for short-selling ban and growth-tailored regulations https://mtimes.net/article/1408 MTIMES Global en 2026-11-01T00:44:02.307Z Anthropic Expands AI Business into Drug Discovery, from Antibody Optimization to Clinical Support https://mtimes.net/article/1406 MTIMES Global en 2026-10-31T06:20:14.303Z 700선 위기 KOSDAQ…왜 상승세를 지키지 못했나 https://mtimes.net/article/1409 MTIMES Global en 2026-11-01T00:45:09.371Z South Korean Battery Makers Pivot to LFP and ESS Amid Evolving Demand https://mtimes.net/article/1405 MTIMES Global en 2026-10-30T22:59:36.025Z Wall Street Sells Off Big Tech Despite Solid Earnings: The Growing Skepticism Over AI ROI https://mtimes.net/article/1407 MTIMES Global en 2026-11-01T00:27:26.139Z South Korea Pledges ₩5 Trillion to Boost AI Adoption Among Small Manufacturers https://mtimes.net/article/1394 MTIMES Global en 2026-10-30T00:15:41.264Z Telecom Base Stations Evolve Into AI Infrastructure: A New Semiconductor Market Beyond Data Centers https://mtimes.net/article/1379 MTIMES Global en 2026-10-29T00:04:24.702Z Renewable Energy Growth Faces First Potential Slowdown in Five Years Due to Grid Bottlenecks https://mtimes.net/article/1377 MTIMES Global en 2026-10-28T22:59:31.985Z Wall Street Sees December Rate Hike Despite Fed Pause, Divided on 2024 Outlook https://mtimes.net/article/1343 MTIMES Global en 2026-10-26T06:39:58.568Z Robust AI Chip Demand Hits Financing Snag as Borrowing Costs Surge https://mtimes.net/article/1241 MTIMES Global en 2026-10-15T00:54:49.439Z Big Insight: Assessing the Market Impact of the September U.S. CPI Report https://mtimes.net/article/1214 MTIMES Global en 2026-10-12T23:51:43.945Z Mezzion Pharma Targets First-ever Fontan Treatment Approval, Leveraging Clinical Expertise for Global Commercialization https://mtimes.net/article/1162 MTIMES Global en 2026-10-06T22:55:31.843Z HLB Therapeutics CEO An Ki-hong: “RGN-259 Set to Become First-Line Choice for Neurotrophic Keratitis” https://mtimes.net/article/1146 MTIMES Global en 2026-10-05T21:42:37.847Z Global Phase 3 Watch: HLB Therapeutics Eyes $1.7B U.S. Neurotrophic Keratitis Market with November RGN-259 Readout https://mtimes.net/article/1141 MTIMES Global en 2026-10-03T02:18:40.463Z [K-Bio Global Phase 3] Fred Kim, Head of AriBio US: "AR1001 Aims to Become the First-Line Therapy for Early Alzheimer’s" https://mtimes.net/article/1135 MTIMES Global en 2026-10-02T08:03:16.376Z ARBIOW's AR1001 Aims for November Milestone as Commercialization Pace Quickens https://mtimes.net/article/1128 MTIMES Global en 2026-10-02T00:05:00.829Z KOSPI Edges Up, Yet 7 in 10 Stocks Fall as Semiconductor Concentration Deepens https://mtimes.net/article/1117 MTIMES Global en 2026-09-30T23:01:34.700Z Beyond Micron’s Strong Earnings: Long-Term Supply Contracts Rush in Through 2031 https://mtimes.net/article/1113 MTIMES Global en 2026-09-30T09:33:40.115Z AI Works Even When the App is Closed: Big Tech Shifts Focus to Persistent Autonomous Agents https://mtimes.net/article/1348 MTIMES Global en 2026-10-26T21:48:11.893Z HanAll Biopharma’s Batoclimab Wins Approval in China; Next-Gen Antibody Progresses to Global Phase 3 Trials https://mtimes.net/article/1396 MTIMES Global en 2026-10-30T02:34:19.895Z Hanmi Semiconductor Faces Earnings Miss Despite HBM Boom https://mtimes.net/article/1382 MTIMES Global en 2026-10-29T05:10:49.557Z Samsung Electronics Slumps as Shareholder Return Plan Disappoints Investors; KOSPI Falls Back Below 6,000 https://mtimes.net/article/1398 MTIMES Global en 2026-10-30T05:30:59.866Z Alteogen’s SC Technology Gains Traction as Keytruda SC Sales Top $830 Million https://mtimes.net/article/1363 MTIMES Global en 2026-10-28T02:32:00.487Z SK hynix Secures Supply Through 2029 as Operating Margin Approaches 80% https://mtimes.net/article/1402 MTIMES Global en 2026-10-30T08:34:53.422Z Even a $4.8B Acquisition Wasn’t Enough: Why BioMarin Chose Hanmi and GC Biopharma https://mtimes.net/article/1388 MTIMES Global en 2026-10-29T09:56:27.659Z Multibillion-Won Bet on JYP? Doubts Linger Over Nexroc’s Spree of Takeover Bids https://mtimes.net/article/1384 MTIMES Global en 2026-10-29T07:08:14.223Z LG Electronics pivots toward automotive and data centers as business portfolio shifts https://mtimes.net/article/1352 MTIMES Global en 2026-10-27T01:37:57.821Z HLB's Rivoceranib Shows 11.8-Month PFS in Rare Cancer at ESMO 2026; Repertu Preps for US Launch https://mtimes.net/article/1386 MTIMES Global en 2026-10-29T08:36:38.123Z Alphabet Shares Plunge Despite Doubling Cloud Revenue as Ad Growth Slows and Capex Weighs https://mtimes.net/article/1371 MTIMES Global en 2026-10-28T08:27:02.337Z HanAll BioPharma Posts 124.2 Bln Won in Cumulative Q3 Revenue Driven by Strong Drug Sales https://mtimes.net/ja/article/1413 MTIMES Global ja 2026-11-01T23:10:21.054Z スモールインサイトリサーチ「シュ프리마、顔を越えて空間を読む」 https://mtimes.net/ja/article/1410 MTIMES Global ja 2026-11-01T03:17:17.179Z 危機に直面するKOSDAQ…空売り禁止の請願、成長市場に合致する基準を要求 https://mtimes.net/ja/article/1408 MTIMES Global ja 2026-11-01T00:44:02.307Z アンソロピック、新薬開発でAI事業を拡大へ…抗体最適化から臨床支援まで https://mtimes.net/ja/article/1406 MTIMES Global ja 2026-10-31T06:20:14.303Z 700割れの危機に瀕するKOSDAQ…なぜ上昇基調を維持できなかったのか https://mtimes.net/ja/article/1409 MTIMES Global ja 2026-11-01T00:45:09.371Z 韓国バッテリー、素材・設備の転換スピードアップ…ハイニッケルラインもLFPへ https://mtimes.net/ja/article/1405 MTIMES Global ja 2026-10-30T22:59:36.025Z 業績好調でも崩れた米ハイテク株…ウォール街はなぜ売り越したのか https://mtimes.net/ja/article/1407 MTIMES Global ja 2026-11-01T00:27:26.139Z 中小製造業のAI導入率1％…政府、5兆ウォン投じ10倍へ拡大 https://mtimes.net/ja/article/1394 MTIMES Global ja 2026-10-30T00:15:41.264Z 通信基地局もAIインフラに…データセンター外に新たな半導体市場が開幕 https://mtimes.net/ja/article/1379 MTIMES Global ja 2026-10-29T00:04:24.702Z 過去最大を記録した再生可能エネルギー、5年ぶりに失速か…送電網が足かせに https://mtimes.net/ja/article/1377 MTIMES Global ja 2026-10-28T22:59:31.985Z ウォール街、FRBの据え置き後も12月利上げを予想…来年の利下げパスには見方も分かれる https://mtimes.net/ja/article/1343 MTIMES Global ja 2026-10-26T06:39:58.568Z AI半導体需要は堅調も…高まる資金調達の負担 https://mtimes.net/ja/article/1241 MTIMES Global ja 2026-10-15T00:54:49.439Z [ビッグインサイト-メル] 9月CPIが発表された。結果を徹底分析する https://mtimes.net/ja/article/1214 MTIMES Global ja 2026-10-12T23:51:43.945Z 【Kバイオグローバル第3相 | 企画5】メジオン、初のフォンタン術治療薬に挑戦…臨床経験を商業化の競争力に https://mtimes.net/ja/article/1162 MTIMES Global ja 2026-10-06T22:55:31.843Z [Kバイオ グローバル第3相 | 企画4] HLBテラピューティクス代表 アン・ギホン「RGN-259、神経栄養性角膜炎（NK）初期治療の第1選択肢に期待」 https://mtimes.net/ja/article/1146 MTIMES Global ja 2026-10-05T21:42:37.847Z 【Kバイオ グローバル第3相｜企画3】HLBセラピューティクス、米2.3兆ウォン規模のNK治療薬市場に挑戦…11月にRGN-259の米国第3相結果に注目 https://mtimes.net/ja/article/1141 MTIMES Global ja 2026-10-03T02:18:40.463Z 【Kバイオ グローバル第3相｜企画2】アリバイオ米州支社長フレッド・キム氏「AR1001、初期アルツハイマーの1次治療薬を目指す」 https://mtimes.net/ja/article/1135 MTIMES Global ja 2026-10-02T08:03:16.376Z 【Kバイオ グローバル第3相 | 企画1】アーリバイオ「AR1001」、11月に成績表公開へ…商業化準備に拍車 https://mtimes.net/ja/article/1128 MTIMES Global ja 2026-10-02T00:05:00.829Z KOSPIは上昇も10社中7社が下落、再び強まる「半導体偏重」 https://mtimes.net/ja/article/1117 MTIMES Global ja 2026-09-30T23:01:34.700Z マイクロンの好業績の裏に一段と強いシグナル…2031年物量まで長期契約の「ラッシュ」 https://mtimes.net/ja/article/1113 MTIMES Global ja 2026-09-30T09:33:40.115Z 「アプリを閉じてもAIは働く」…ビッグテック、今度は「常時稼働型エージェント」で競争 https://mtimes.net/ja/article/1348 MTIMES Global ja 2026-10-26T21:48:11.893Z [Kバイオ 글로벌 3상 | 기획6] ハンオルバイオファーマ、バトクリマブが中国で承認取得…次世代抗体はグローバル治験第3相を進行 https://mtimes.net/ja/article/1396 MTIMES Global ja 2026-10-30T02:34:19.895Z 漢美半導体、HBM好況下でアーニングショック…第4四半期の反発はあるか https://mtimes.net/ja/article/1382 MTIMES Global ja 2026-10-29T05:10:49.557Z 株主還元策に失望のサムスン電子が急落…KOSPIも6000割れ https://mtimes.net/ja/article/1398 MTIMES Global ja 2026-10-30T05:30:59.866Z アルテオジェンの「KEYTRUDA SC」、四半期売上高が1兆ウォンを突破…ロイヤリティ数千億ウォン時代の幕開けか https://mtimes.net/ja/article/1363 MTIMES Global ja 2026-10-28T02:32:00.487Z SKハイニックス、3年先のメモリーまで受注完売…営業利益率は80%に肉薄 https://mtimes.net/ja/article/1402 MTIMES Global ja 2026-10-30T08:34:53.422Z 48億ドル買収でも物足りなかったのか…バイオマリンがハンミ・緑十字を選択した理由 https://mtimes.net/ja/article/1388 MTIMES Global ja 2026-10-29T09:56:27.659Z JYPに数千億ウォンをベット？…ネックスロックの「買収ラッシュ」に疑問 https://mtimes.net/ja/article/1384 MTIMES Global ja 2026-10-29T07:08:14.223Z LG電子、車載からデータセンターへ…事業の重心がシフト https://mtimes.net/ja/article/1352 MTIMES Global ja 2026-10-27T01:37:57.821Z [ESMO 2026分析] HLBのリボセラニブ、希少がんでPFS11.8カ月…リピックトゥの米発売準備へ https://mtimes.net/ja/article/1386 MTIMES Global ja 2026-10-29T08:36:38.123Z グーグル、クラウド売上高倍増も株価急落…広告鈍化と投資負担が重石に https://mtimes.net/ja/article/1371 MTIMES Global ja 2026-10-28T08:27:02.337Z ハンオルバイオファーマ、医薬品販売好調の中、第3四半期までの累計売上高1242億ウォン https://mtimes.net/zh/article/1413 MTIMES Global zh-cn 2026-11-01T23:10:21.054Z Small Insight Research：“ Suprema：超越面部，读取空间” https://mtimes.net/zh/article/1410 MTIMES Global zh-cn 2026-11-01T03:17:17.179Z 陷入危机的KOSDAQ…禁空令请愿频发，市场呼吁契合成长特性的监管标准 https://mtimes.net/zh/article/1408 MTIMES Global zh-cn 2026-11-01T00:44:02.307Z Anthropic拓宽AI业务至新药研发：从抗体优化到临床支持 https://mtimes.net/zh/article/1406 MTIMES Global zh-cn 2026-10-31T06:20:14.303Z KOSDAQ面临跌破700点危机……为何无法守住涨势？ https://mtimes.net/zh/article/1409 MTIMES Global zh-cn 2026-11-01T00:45:09.371Z 韩国电池产业加速素材与设备转型：高镍产线转产LFP https://mtimes.net/zh/article/1405 MTIMES Global zh-cn 2026-10-30T22:59:36.025Z 业绩虽好却崩盘的美国科技股……华尔街为何抛售？ https://mtimes.net/zh/article/1407 MTIMES Global zh-cn 2026-11-01T00:27:26.139Z 中小制造业AI采用率仅1%…韩国政府将斥资5万亿韩元提升10倍 https://mtimes.net/zh/article/1394 MTIMES Global zh-cn 2026-10-30T00:15:41.264Z 通信基站也将变身AI基础设施…数据中心之外的新半导体市场正被开启 https://mtimes.net/zh/article/1379 MTIMES Global zh-cn 2026-10-29T00:04:24.702Z 创下历史新高的可再生能源，时隔5年将遇挫？输电网成“绊脚石” https://mtimes.net/zh/article/1377 MTIMES Global zh-cn 2026-10-28T22:59:31.985Z 华尔街：美联储按兵不动后仍预计12月加息，对明年降息路径存在分歧 https://mtimes.net/zh/article/1343 MTIMES Global zh-cn 2026-10-26T06:39:58.568Z AI半导体需求依然强劲……融资压力却在不断加大 https://mtimes.net/zh/article/1241 MTIMES Global zh-cn 2026-10-15T00:54:49.439Z [Big Insight-Mer] 9月CPI数据出炉：深度解析核心结果 https://mtimes.net/zh/article/1214 MTIMES Global zh-cn 2026-10-12T23:51:43.945Z 【K-Bio全球三期 | 策划5】Mezzion挑战首款Fontan术治疗药物…以临床经验转化为商业化竞争力 https://mtimes.net/zh/article/1162 MTIMES Global zh-cn 2026-10-06T22:55:31.843Z [K-Bio全球III期临床 | 策划4] HLB Therapeutics代表安基洪：“期待RGN-259成为NK初期治疗的首选方案” https://mtimes.net/zh/article/1146 MTIMES Global zh-cn 2026-10-05T21:42:37.847Z 【K-Bio全球III期临床｜策划3】HLB Therapeutics进军美国2.3万亿韩元NK治疗药物市场…11月RGN-259美国III期临床结果备受瞩目 https://mtimes.net/zh/article/1141 MTIMES Global zh-cn 2026-10-03T02:18:40.463Z 【K-Bio全球III期临床｜策划2】阿里拜尔（AｒｉBio）美洲支社长Fred Kim：“AR1001旨在成为早期阿尔茨海默病一线治疗药物” https://mtimes.net/zh/article/1135 MTIMES Global zh-cn 2026-10-02T08:03:16.376Z 【K-Bio全球三期临床 | 策划1】ArisBio AR1001将于11月揭晓成绩单……商业化准备加速 https://mtimes.net/zh/article/1128 MTIMES Global zh-cn 2026-10-02T00:05:00.829Z KOSPI上涨但十分之七个股下跌，“半导体独大”现象再度加剧 https://mtimes.net/zh/article/1117 MTIMES Global zh-cn 2026-09-30T23:01:34.700Z 美光强劲财报背后的更强信号：长期合约“涌向”2031年交付量 https://mtimes.net/zh/article/1113 MTIMES Global zh-cn 2026-09-30T09:33:40.115Z “关掉App，AI也在干活”……科技巨头竞逐“常驻型代理” https://mtimes.net/zh/article/1348 MTIMES Global zh-cn 2026-10-26T21:48:11.893Z [K-生物医药全球三期 | 策划6] 韩올生物医药파마 Batoclimab获中国批准…次代抗体正在推进全球三期临床 https://mtimes.net/zh/article/1396 MTIMES Global zh-cn 2026-10-30T02:34:19.895Z 韩美半导体，即便HBM市场火热也难逃“财报冲击”…第四季度能否反弹？ https://mtimes.net/zh/article/1382 MTIMES Global zh-cn 2026-10-29T05:10:49.557Z 三星电子未能满足股东回报预期导致股价暴跌……KOSPI指数跌破6000点 https://mtimes.net/zh/article/1398 MTIMES Global zh-cn 2026-10-30T05:30:59.866Z Alteogen“QLEX”季度销售额突破1万亿韩元……能否开启数千亿韩元版税时代 https://mtimes.net/zh/article/1363 MTIMES Global zh-cn 2026-10-28T02:32:00.487Z SK海力士，3年后存储需求排队等候……营业利润率逼近80% https://mtimes.net/zh/article/1402 MTIMES Global zh-cn 2026-10-30T08:34:53.422Z 收购48亿美元还不够吗……BioMarin为何选择韩美与绿十字 https://mtimes.net/zh/article/1388 MTIMES Global zh-cn 2026-10-29T09:56:27.659Z 对JYP砸数千亿韩元？…Nexroc“收购热潮”引发质疑 https://mtimes.net/zh/article/1384 MTIMES Global zh-cn 2026-10-29T07:08:14.223Z LG电子：从汽车延伸至数据中心，业务重心迎来转变 https://mtimes.net/zh/article/1352 MTIMES Global zh-cn 2026-10-27T01:37:57.821Z [ESMO 2026分析] HLB Rivoceranic在罕见癌中PFS达11.8个月…正为Repertuzumab（Ribociclib同类/Ripertuzumab）美国上市做准备 https://mtimes.net/zh/article/1386 MTIMES Global zh-cn 2026-10-29T08:36:38.123Z 谷歌云业务营收翻倍但股价大跌……广告增长放缓及投资压力所致 https://mtimes.net/zh/article/1371 MTIMES Global zh-cn 2026-10-28T08:27:02.337Z 韩올生物医药파마（HanAll Biopharma）：得益于医药销售强劲，前三季度累计营收达1242亿韩元